Lonza and Teva Collaborate on Biosimilars
Teva (Jerusalem, Israel), the world?s largest generics company, and Lonza (Basel, Switzerland) have formed a joint venture to develop, manufacture, and market biosimilars.
Teva (Jerusalem, Israel), the world’s largest generics company, and Lonza (Basel, Switzerland) have formed a joint venture to develop, manufacture, and market biosimilars.
Lonza, one of the largest biopharmaceutical contract manufacturing organizations, is confident that its foray into biosimilars will not interfere with its ongoing work for innovator companies. To protect its customers’ intellectual property, Lonza will not develop biosimilars for any product made by its current customers.
“The joint venture has been very carefully designed so that we cannot work on any biosimilar product for which we do not have the legal or ethical freedom to do so,” said Dominik Werner, a Lonza spokesperson. “Our work for innovator companies remains our core business.”
While developing its strategy for the biosimilars market, Lonza discussed the idea with current customers, and came to the conclusion that they would not be scared off.
“Innovator companies understand the attractiveness of the biosimilars market,” Werner said. “There has been a mindshift, and many of them are also taking steps in this direction.”
Pending regulatory approval of the partnership, activity in the joint venture will begin this quarter, and the companies expect their first product will be approved by 2014.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.
